QuickLinks -- Click here to rapidly navigate through this document

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 3, 2004

Array BioPharma Inc.
(Exact name of registrant as specified in its charter)

Delaware   000-31979   84-1460811
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

 

 

 

 
3200 Walnut Street, Boulder, Colorado   80301
(Address of Principal Executive Offices)   (Zip Code)

Registrant's telephone number, including area code: (303) 381-6600

(Former Name or Former Address, if Changed Since Last Report)


ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

        On May 3, 2004, the registrant issued a press release reporting financial results for the third quarter of fiscal year 2004, the full text of which is attached hereto as Exhibit 99.1.

        The information in this Form 8-K and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

 

ARRAY BIOPHARMA INC.

Date: May 3, 2004

 

By:

 

/s/  
ROBERT E. CONWAY      
Robert E. Conway
Chief Executive Officer


EXHIBIT INDEX

Exhibit No.

   
99.1   Press release dated May 3, 2004 entitled "Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2004"



QuickLinks

SIGNATURES
EXHIBIT INDEX